ERBB2 and gastric cancer: However, unlike the success of various HER2-targeted agents in treating metastatic breast cancer [4, 5], only trastuzumab has been established to provide significant efficacy in HER2-positive GC patients, though trastuzumab resistance is increasingly common [6].